Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Quantifying the federal minimal risk standard: Implications for pediatric research without a prospect of direct benefit

Article Abstract:

The US federal regulations allow institutional review boards (IRBs) to approve pediatric research that does not offer a prospect of direct benefit only when the risks are minimal or when the risks are a minor increase over minimal risk. Data suggest that IRBs may be categorizing as greater than minimal risk many research procedures that qualify, under the federal regulations, as posing no greater than minimal risk to pediatric participants.

Author: Emanuel, Ezekiel J., Thompson, Kimberly M., Wendler, David, Belsky, Leah
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
Product standards, safety, & recalls, Standards, Clinical trials

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


How do institutional review boards apply the federal risk and benefit standards for pediatric research?

Article Abstract:

Different institutional review boards (IRBs) interpret the federal laws governing research on children differently, according to a survey of the chairpersons of 188 IRBs. The laws state that no study on children should be approved if it does not benefit the child and would expose the child to more than a minor increase over minimal risk of injury. Unfortunately, the laws are vague in defining what constitutes a benefit or a risk.

Author: Wilfond, Benjamin, Shah, Seema, Whittle, Amy, Gensler, Gary, Wendler, David
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Pediatric drug studies required by law

Article Abstract:

The US Food and Drug Administration now has the power to require pharmaceutical companies to test all drugs that will be given to children. Some doctors believe the FDA should create an expert panel to oversee this research. All researchers will have to follow strict guidelines to ensure that children will not be harmed by the drugs.

Author: Hampton, Tracy
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
Pharmaceutical industry, Pediatric pharmacology

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Pediatric research, Laws, regulations and rules, Government regulation
Similar abstracts:
  • Abstracts: Michigan considers state ergonomics standard. No easy NRR determination for dual hearing protection
  • Abstracts: Ensuring more holistic care for patients with dyspnoea. The Experience of being a suspended nurse. Risk awareness is a vital factor in fall prevention
  • Abstracts: Making stepfamilies work. Discipline strategies that really work. The new face of fatherhood
  • Abstracts: Network links doctors, disabled job seekers. Small practices can opt for simple, safe retirement plans
  • Abstracts: Ethical considerations in publishing research involving human subjects. Demographic and prenatal factors of patients with cleft lip and cleft palate: a pilot study
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.